tiprankstipranks
Edwards Lifesciences (MX:EW)
:EW
Mexico Market
EW
Edwards Lifesciences
RESEARCH TOOLSreports

Edwards Lifesciences (EW) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

EW Analyst Ratings

Strong Buy
18Ratings
Strong Buy
15 Buy
3 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Edwards
Lifesciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$1,751.63
▲(11.07% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $1,751.63 with a high forecast of $1,869.54 and a low forecast of $1,444.64. The average price target represents a 11.07% change from the last price of $1,577.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1364":"$1,364","1617":"$1,617","1870":"$1,870","1490.5":"$1,490.5","1743.5":"$1,743.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1869.5400933,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.87K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1751.631598779375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1444.64461755,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.44K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1364,1490.5,1617,1743.5,1870],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1577,1599.5030841,1622.0061682,1644.5092523,1667.0123364,1689.5154205000001,1712.0185046000001,1734.5215887,1757.0246728,1779.5277569,1802.030841,1824.5339251,1847.0370092,{"y":1869.5400933,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1577,1590.4331999061058,1603.8663998122115,1617.2995997183173,1630.732799624423,1644.1659995305288,1657.5991994366345,1671.0323993427405,1684.4655992488463,1697.898799154952,1711.3319990610578,1724.7651989671635,1738.1983988732693,{"y":1751.631598779375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1577,1566.8188167346154,1556.6376334692309,1546.456450203846,1536.2752669384615,1526.094083673077,1515.9129004076924,1505.7317171423076,1495.550533876923,1485.3693506115385,1475.188167346154,1465.0069840807691,1454.8258008153846,{"y":1444.64461755,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1525.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1372,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1372,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1585.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1562.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1397.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1365.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1474.23,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1427,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1501,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1518.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1465.83,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1577,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,870Average Price Target$1,752Lowest Price Target$1,445
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on MX:EW
Matthew Taylor
Jefferies
Jefferies
$1,784.56
Buy
13.16%
Upside
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)
Citi Analyst forecast on MX:EW
Joanne Wuensch
Citi
Citi
$1,869.54
Buy
18.55%
Upside
Reiterated
09/10/26
Edwards Lifesciences (EW) Gets a Buy from Citi
William Blair Analyst forecast on MX:EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
09/10/26
CMS TAVR Coverage Expansion and Asymptomatic AS Inclusion Underpin Vazquez’s Buy Rating on Edwards Lifesciences
BTIG Analyst forecast on MX:EW
Marie Thibault
BTIG
BTIG
$1,869.54
Buy
18.55%
Upside
Reiterated
09/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Labcorp Holdings (NYSE: LH) and Edwards Lifesciences (NYSE: EW)
Canaccord Genuity Analyst forecast on MX:EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
$1,444.64
Hold
-8.39%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on MX:EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
$1,784.56
Buy
13.16%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on MX:EW
Patrick Wood
UBS
UBS
$1,529.62→$1,869.54
Buy
18.55%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on MX:EW
Adam Maeder
Piper Sandler
Piper Sandler
$1,699.58→$1,716.58
Buy
8.85%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Oppenheimer Analyst forecast on MX:EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Leerink Partners Analyst forecast on MX:EW
Mike Kratky
Leerink Partners
Leerink Partners
$1,478.64→$1,716.58
Buy
8.85%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Truist Financial Analyst forecast on MX:EW
Richard Newitter
Truist Financial
Truist Financial
$1,614.6
Hold
2.38%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Stifel Nicolaus Analyst forecast on MX:EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$1,869.54
Buy
18.55%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
TD Cowen Analyst forecast on MX:EW
Josh Jennings
TD Cowen
TD Cowen
$1,767.57
Buy
12.08%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on MX:EW
Shagun Singh Chadha
RBC Capital
RBC Capital
$1,869.54
Buy
18.55%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on MX:EW
Travis Steed
Bank of America Securities
Bank of America Securities
$1,699.58
Buy
7.77%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on MX:EW
Matthew Taylor
Jefferies
Jefferies
$1,784.56
Buy
13.16%
Upside
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)
Citi Analyst forecast on MX:EW
Joanne Wuensch
Citi
Citi
$1,869.54
Buy
18.55%
Upside
Reiterated
09/10/26
Edwards Lifesciences (EW) Gets a Buy from Citi
William Blair Analyst forecast on MX:EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
09/10/26
CMS TAVR Coverage Expansion and Asymptomatic AS Inclusion Underpin Vazquez’s Buy Rating on Edwards Lifesciences
BTIG Analyst forecast on MX:EW
Marie Thibault
BTIG
BTIG
$1,869.54
Buy
18.55%
Upside
Reiterated
09/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Labcorp Holdings (NYSE: LH) and Edwards Lifesciences (NYSE: EW)
Canaccord Genuity Analyst forecast on MX:EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
$1,444.64
Hold
-8.39%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on MX:EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
$1,784.56
Buy
13.16%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on MX:EW
Patrick Wood
UBS
UBS
$1,529.62→$1,869.54
Buy
18.55%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on MX:EW
Adam Maeder
Piper Sandler
Piper Sandler
$1,699.58→$1,716.58
Buy
8.85%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Oppenheimer Analyst forecast on MX:EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Leerink Partners Analyst forecast on MX:EW
Mike Kratky
Leerink Partners
Leerink Partners
$1,478.64→$1,716.58
Buy
8.85%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Truist Financial Analyst forecast on MX:EW
Richard Newitter
Truist Financial
Truist Financial
$1,614.6
Hold
2.38%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Stifel Nicolaus Analyst forecast on MX:EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$1,869.54
Buy
18.55%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
TD Cowen Analyst forecast on MX:EW
Josh Jennings
TD Cowen
TD Cowen
$1,767.57
Buy
12.08%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on MX:EW
Shagun Singh Chadha
RBC Capital
RBC Capital
$1,869.54
Buy
18.55%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on MX:EW
Travis Steed
Bank of America Securities
Bank of America Securities
$1,699.58
Buy
7.77%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
JAZZJazz Pharmaceuticals
AXGNAxoGen
ARDXArdelyx
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months
Adam MaederPiper Sandler
Success Rate
18/28 ratings generated profit
64%
Average Return
+1.41%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +1.41% per trade.
1 Year
Adam MaederPiper Sandler
Success Rate
23/28 ratings generated profit
82%
Average Return
+7.71%
Copying Adam Maeder's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +7.71% per trade.
2 Years
Adam MaederPiper Sandler
Success Rate
20/28 ratings generated profit
71%
Average Return
+8.10%
Copying Adam Maeder's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +8.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
30
40
39
34
23
Hold
3
5
6
7
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
45
45
41
28
In the current month, EW has received 23 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 1,751.63.
Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $12.54 with a range of $12.24 to $13.10. The previous quarter’s EPS was $13.26. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.
Next quarter’s earnings estimate for EW is $12.54 with a range of $12.24 to $13.10. The previous quarter’s EPS was $13.26. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $28.50B with a range of $28.04B to $28.99B. The previous quarter’s sales results were $29.59B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.
Next quarter’s sales forecast for EW is $28.50B with a range of $28.04B to $28.99B. The previous quarter’s sales results were $29.59B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is MX:EW’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 1,751.63.
    What is MX:EW’s upside potential, based on the analysts’ average price target?
    Edwards Lifesciences has 11.07% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Edwards Lifesciences a Buy, Sell or Hold?
          Edwards Lifesciences has a consensus rating of Strong Buy, which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Edwards Lifesciences’s share price target?
            The average share price target for Edwards Lifesciences is 1,751.63. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,869.54 ,and the lowest forecast is $1,444.64. The average share price target represents 11.07% Increase from the current price of $1,577.
              What do analysts say about Edwards Lifesciences?
              Edwards Lifesciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Edwards Lifesciences?
                To buy shares of MX:EW, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.